Community and Systems-level HIV Prevention in Peru

Sponsor
University of California, San Francisco (Other)
Overall Status
Completed
CT.gov ID
NCT03774160
Collaborator
Universidad Peruana Cayetano Heredia (Other)
458
1
2
45.8
10

Study Details

Study Description

Brief Summary

This project involves adapting 3 new intervention components, and then testing them, in combination with a multi-level, community-based intervention, to promote HIV prevention and sexual health among men who have sex with men and transgender women in Lima, Peru. The total intervention has a community-based intervention and a systems-level intervention at the hospital where people living with HIV get care and medications.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Generacion Actual
N/A

Detailed Description

Mpowerment (MP) is an evidence-based community-level, structural, social and behavioral intervention for HIV prevention for young men who have sex with men (MSM). MP targets individual and community empowerment and community mobilization, self-affirmation, sexual self-knowledge and creation of a supportive and affirming social environment. MP has been widely used in the U.S. but not in Peru, with the exception of earlier pilot research. In the earlier research, MP was adapted for the sociocultural issues facing MSM and transgender (trans) women in Peru, and only focused risk reduction and increasing HIV testing. In addition to the MP (which is called the community-based intervention), a health systems component has been added. The health systems includes (1) sensitization of hospital staff (where people living with HIV obtain their medication) to the issues facing transgender women and MSM; (2) the use of Navigators, who help MSM and trans women at the hospital navigate the system of care and remain in care; and (3) a focus on "positive prevention", in which providers talk about the positive aspects of maintaining in care and being virally suppressed instead of only talking about "avoiding death." There is a 2.5 year implementation of the intervention, called "Projecto Orgullo Plus" or Project Pride Plus, which involves a longitudinal cohort of MSM/trans in two large districts of Lima, Peru. Primary outcomes will be unprotected anal sex and HIV testing. Secondary outcomes will be self-reported visits to hospital for care and adherence to medications.

Study Design

Study Type:
Interventional
Actual Enrollment :
458 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Two different districts are being used, one in which the intervention is implemented and the other is a no-intervention comparison site.Two different districts are being used, one in which the intervention is implemented and the other is a no-intervention comparison site.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Combination HIV Prevention, Linking Prevention and Care, for Hispanic Men
Actual Study Start Date :
Apr 6, 2017
Actual Primary Completion Date :
Jan 30, 2021
Actual Study Completion Date :
Jan 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Generacion Actual

Generacion Actual includes Community-based and a Health Systems Components. This multi-level intervention reaches out to all MSM/trans by mobilizing them to encourage friends to reduce risk behavior and increase HIV testing, and for HIV+ friends, encourage them to link, stay in care, and take medications regularly. The community based component includes a leadership group, community space, community mobilization events, and group sessions to address a variety of psychosocial issues as well as HIV literacy. The Health Systems component includes sensitization of the HIV testing and care staff to working with MSM and trans, Navigators to help MSM/trans to navigate the complex health system; and positive prevention training of providers; all evidence-based approaches.

Behavioral: Generacion Actual
See description in arm description.
Other Names:
  • Mpowerment
  • No Intervention: Comparison

    No intervention is implemented in the comparison arm.

    Outcome Measures

    Primary Outcome Measures

    1. condomless anal sex [37 months post-baseline]

      condomless anal sex with HIV+ or unknown status partners, assessed via questionnaire

    2. HIV testing ever [37 months post-baseline]

      if have ever tested for HIV

    3. HIV testing frequency [37 months post-baseline]

      frequency of HIV testing by report on questionnaire

    Secondary Outcome Measures

    1. If enrolled in care [37 months post-baseline]

      Has the person, after testing HIV+, enroll in care

    2. Seeking regular HIV care [37 months post-baseline]

      If have seen HIV provider recently by report on questionnaire

    3. Taking medications adherently [37 months post-baseline]

      If have missed any times of taking HIV medications by report on questionnaire

    4. If virally suppressed [37 months post-baseline]

      Has the person been told that he/she is virally suppressed

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 40 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Must live in either East Lima District or South Lima District

    • identify as man who has sex with men or transgender woman who has sex with men

    • be between the ages of 18 - 40

    Exclusion Criteria:
    • not residing in either East or South District of Lima

    • not MSM or transgender woman

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cayetano Heredia University Lima Peru

    Sponsors and Collaborators

    • University of California, San Francisco
    • Universidad Peruana Cayetano Heredia

    Investigators

    • Principal Investigator: Susan M Kegeles, PhD, University of California, San Francisco

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of California, San Francisco
    ClinicalTrials.gov Identifier:
    NCT03774160
    Other Study ID Numbers:
    • 5R01MH109401-04
    First Posted:
    Dec 12, 2018
    Last Update Posted:
    Apr 26, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Apr 26, 2022